Original language | English |
---|---|
Pages (from-to) | 674-682 |
Number of pages | 9 |
Journal | Cancer Discovery |
Volume | 14 |
Issue number | 4 |
DOIs | |
State | Published - 1 Apr 2024 |
All Science Journal Classification (ASJC) codes
- Oncology
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Cancer Discovery, Vol. 14, No. 4, 01.04.2024, p. 674-682.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Cancer Hallmarks
T2 - Piecing the Puzzle Together
AU - Alcolea, Maria P.
AU - Alonso-Curbelo, Direna
AU - Ambrogio, Chiara
AU - Bullman, Susan
AU - Correia, Ana Luísa
AU - Ernst, Aurélie
AU - Halbrook, Christopher J.
AU - Kelly, Gemma L.
AU - Lund, Amanda W.
AU - Quail, Daniela F.
AU - Ruscetti, Marcus
AU - Shema, Efrat
AU - Stromnes, Ingunn M.
AU - Tam, Wai Leong
N1 - C. Ambrogio reports research fees from Revolution Medicines, Aelin Therapeutics, Verastem, Roche, and Boehringer-Ingelheim. G.L. Kelly is an employee of WEHI, which receives milestone and royalty payments related to venetoclax; in addition, G.L. Kelly has received research funding from Servier. A.W. Lund reports consulting services for AGS Therapeutics, Inc. I.M. Stromnes reports personal fees from Immunogenesis and other support from Luminary Therapeutics outside the submitted work; in addition, I.M. Stromnes has a patent for Mesothelin TCR issued, licensed, and with royalties paid, a second patent for Mesothelin TCR issued, a patent for Chimeric costimulatory receptors issued and with royalties paid, a patent for Trex mouse model pending, and a patent for Mutant KRAS TCR issued, licensed, and with royalties paid. E. Shema reports personal fees from SEQLL outside the submitted work. S. Bullman reports personal fees from AstraZeneca and personal fees from Roche outside the submitted work; in addition, S. Bullman has a patent for PCT/US2018/042966 pending and a patent for F053-0188USP1/22-158-US-PSP pending. M. Ruscetti reports personal fees from Boehringer Ingelheim outside the submitted work. No disclosures were reported by the other authors.
PY - 2024/4/1
Y1 - 2024/4/1
UR - http://www.scopus.com/inward/record.url?scp=85190077146&partnerID=8YFLogxK
U2 - https://doi.org/10.1158/2159-8290.CD-24-0097
DO - https://doi.org/10.1158/2159-8290.CD-24-0097
M3 - مقالة
C2 - 38571410
SN - 2159-8274
VL - 14
SP - 674
EP - 682
JO - Cancer Discovery
JF - Cancer Discovery
IS - 4
ER -